在多发性硬化症中进行Rituximab临床试点研究中的药理动力学-药理动力学建模:朝着个性化剂量间隔的方向
Trond Trætteberg Serkland1,2, Silje Skrede1,2, Erik Ingmar Hallin1
1Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
British journal of clinical pharmacology
|June 14, 2025
概括
这项研究开发了多发性硬化症患者里图西马布 (RTX) 的药理动力学-药理动力学 (PKPD) 模型. 该模型描述了患者特定的RTX度和CD19+淋巴细胞计数,有助于个性化剂量策略.
科学领域:
- 药理学 药理学 是一个学科.
- 免疫学 免疫学 免疫学
- 神经学 神经学
背景情况:
- 利图西马布 (RTX) 是用于治疗复发性复发性多发性硬化症 (MS) 的非标签药物.
- 目前在MS中RTX的剂量方案各不相同,观察数据表明可能需要延长和个性化间隔.
- 需要模型来更好地了解MS患者的RTX药理动力学和药理动力学.
研究的目的:
- 开发一个药理动力学-药理动力学 (PKPD) 模型来描述患者特定的RTX度.
- 在MS患者中描述RTX度和CD19+淋巴细胞计数之间的关系.
- 为各成员国提供个性化RTX剂量的基础.
主要方法:
- 一个PKPD模型是使用13名先前未接受治疗的患有复发性复发性多发性硬化症患者的数据开发的.
- 患者接受了1000毫克的RTX静脉注射.
- 在六个月的六个时间点收集血液样本,并使用非线性混合效应建模 (Monolix) 分析RTX度和CD19+淋巴细胞计数.
主要成果:
- 最初的RTX药理动力学最好用一个非线性目标介导消除的单间模型来描述.
- 包括CD19+淋巴细胞作为药理动力学标志物,允许在一个和两个隔间模型之间比较性能.
- 在模型中,发现非特异性清除大约是目标介导清除的十倍.
结论:
- 开发的PKPD模型有效地描述了个人MS患者的RTX度和CD19+淋巴细胞计数.
- 这些模型既适应了长期的淋巴细胞枯竭,也适应了早期的重新繁殖模式.
- 需要进一步的数据来验证和完善这些模型,以预测重新种群动态,并使个人化RTX剂量在MS.
更多相关视频
相关概念视频
Pharmacokinetic Models: Comparison and Selection Criterion
50
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
50
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
64
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
64
Pharmacokinetic Models: Overview
625
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
625
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
34
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
34
Analysis of Population Pharmacokinetic Data
241
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
241
One-Compartment Open Model for IV Bolus Administration: General Considerations
173
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
173


